You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect

https://doi.org/10.1136/annrheumdis-2018-214374

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Handling editor Josef S Smolen

    • VG and MS contributed equally.

    • Contributors VG and MS collected the data and wrote the manuscript. MS and TB analysed the data. TS designed the study and helped in data analysis. All authors critically reviewed the paper and validated the last version of it.

    • Competing interests TS received honoraria as consultant from: Amgen, AbbVie, BMS, Janssen, MSD, Novartis, Pfizer, Roche Chugaï, UCB. TS received a research grant from Pfizer (unrelated to this work). The other authors report no conflicts of interests.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.